Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · Real-Time Price · USD
107.13
+5.09 (4.99%)
Jun 18, 2026, 4:00 PM EDT - Market closed

Mirum Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 14 analysts polled by S&P Global, Mirum Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $145.36. The average 1-year stock price forecast is 35.69% higher than the current stock price, while the lowest is $115 (+7.35%) and the highest is $185 (+72.69%).

Price Target: $145.36 (+35.69%)
Analyst Consensus: Strong Buy
TargetLowAverageMedianHigh
Price$115$145.36$145$185
Change+7.35%+35.69%+35.35%+72.69%

Analyst Ratings

The average analyst rating for Mirum Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

RatingJan '26Feb '26Mar '26Apr '26May '26Jun '26
Strong Buy8888910
Buy233344
Hold000000
Sell000000
Strong Sell000000
Total101111111314

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Morgan Stanley
Morgan Stanley
Buy
Maintains
$150
BuyMaintains$150+40.02%Jun 15, 2026
Citi
Citi
Buy
Maintains
$145
BuyMaintains$145+35.35%Jun 15, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$185
BuyReiterates$185+72.69%Jun 15, 2026
Citizens JMP
Citizens JMP
Buy
Maintains
$140$146
BuyMaintains$140$146+36.28%Jun 15, 2026
Unknown Analyst
J.P. Morgan
No rating
J.P. Morgan
Buy
Initiates
$115
BuyInitiates$115+7.35%May 20, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
675.30M
from 521.31M
Increased by 29.54%
Revenue Next Year
814.44M
from 675.30M
Increased by 20.60%
EPS This Year
-16.33
from -0.47
EPS Next Year
-0.09
from -16.33
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
19.14M77.06M186.37M336.89M521.31M675.30M
Revenue Growth
-302.67%141.85%80.76%54.74%29.54%
Gross Profit
17.24M64.69M139.34M255.25M421.07M546.31M
Gross Margin
90.06%83.94%74.76%75.77%80.77%80.90%
Operating Income
-173.41M-131.22M-109.15M-87.61M-22.14M-881.62M
Net Income
-83.99M-135.67M-163.42M-87.94M-23.36M-910.66M
EPS
-----0.47-16.33
Free Cash Flow
-96.18M-68.57M-91.35M16.67M98.56M-527.50M
No. Analysts
-----12
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High683.4M
Avg675.3M
Low669.0M

Revenue Growth

Revenue Growth202620272028
High
31.1%
Avg
29.5%
Low
28.3%

EPS Forecast

EPS202620272028
High-16.33
Avg-16.33
Low-16.33

EPS Growth

EPS Growth202620272028
High-
Avg-
Low-